{"analyses":[{"ciLowerLimit":"0.448","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.184","groupDescription":"Hazard ratio (A+AVD/ABVD) and 95% CI are based on a stratified Cox's proportional hazard regression model with stratification factors region and number of IPFP risk factors at baseline with treatment as the explanatory variable in the model. Hazard ratio \\<1 favors A+AVD arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.199","paramType":"Hazard Ratio (HR)","paramValue":"0.728","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median and confidence interval was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and confidence interval was not estimable due to low number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"664"},{"groupId":"OG001","value":"670"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of death. Participants without documented death at the time of analysis were censored at the date last known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"OG001","title":"ABVD"}],"paramType":"MEDIAN","populationDescription":"The ITT population included all participants randomized to treatment.","reportingStatus":"POSTED","timeFrame":"Baseline until death (approximately up to 4 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}